Show simple item record

dc.contributor.authorIsing, Christina
dc.contributor.authorVenegas Maldonado, Carmen Jesica
dc.contributor.authorZhang, Shuangshuang
dc.contributor.authorScheiblich, Hannah
dc.contributor.authorSchmidt, Susanne V.
dc.contributor.authorVieira-Saecker, Ana
dc.contributor.authorSchwartz, Stephanie
dc.contributor.authorAlbasset, Shadi
dc.contributor.authorMcManus, Róisín M.
dc.contributor.authorTejera, Dario
dc.contributor.authorGriep, Angelika
dc.contributor.authorSantarelli, Francesco
dc.contributor.authorBrosseron, Frederic
dc.contributor.authorOpitz, Sabine
dc.contributor.authorStunden, James
dc.contributor.authorMerten, Maximilian
dc.contributor.authorKayed, Rakez
dc.contributor.authorGolenbock, Douglas T.
dc.contributor.authorBlum, David
dc.contributor.authorLatz, Eicke
dc.contributor.authorBuée, Luc
dc.contributor.authorHeneka, Michael T.
dc.date.accessioned2026-02-24T08:24:31Z
dc.date.available2026-02-24T08:24:31Z
dc.date.issued2019-11-20
dc.identifier.citationIsing, C., Venegas, C., Zhang, S. et al. NLRP3 inflammasome activation drives tau pathology. Nature 575, 669–673 (2019). https://doi.org/10.1038/s41586-019-1769-zes_ES
dc.identifier.urihttps://hdl.handle.net/10481/111431
dc.descriptionThis work was supported by funding from the Deutsche Forschungsgemeinschaft (DFG) to C.I. (IS 299/3-1) and under Germany’s Excellence Strategy – EXC2151 – 390873048. R.K. received funding from a NIH grant (R01 AG054025), and D.G. and M.T.H. received further funding from a NIH grant (R01 AG059752-02).es_ES
dc.description.abstractAlzheimer's disease is characterized by the accumulation of amyloid-beta in plaques, aggregation of hyperphosphorylated tau in neurofibrillary tangles and neuroinflammation, together resulting in neurodegeneration and cognitive decline1. The NLRP3 inflammasome assembles inside of microglia on activation, leading to increased cleavage and activity of caspase-1 and downstream interleukin-1β release2. Although the NLRP3 inflammasome has been shown to be essential for the development and progression of amyloid-beta pathology in mice3, the precise effect on tau pathology remains unknown. Here we show that loss of NLRP3 inflammasome function reduced tau hyperphosphorylation and aggregation by regulating tau kinases and phosphatases. Tau activated the NLRP3 inflammasome and intracerebral injection of fibrillar amyloid-beta-containing brain homogenates induced tau pathology in an NLRP3-dependent manner. These data identify an important role of microglia and NLRP3 inflammasome activation in the pathogenesis of tauopathies and support the amyloid-cascade hypothesis in Alzheimer's disease, demonstrating that neurofibrillary tangles develop downstream of amyloid-beta-induced microglial activation.es_ES
dc.description.sponsorshipDeutsche Forschungsgemeinschaft (DFG) (IS 299/3-1)es_ES
dc.description.sponsorshipGermany’s Excellence Strategy – EXC2151 – 390873048es_ES
dc.description.sponsorshipNIH grant (R01 AG054025)es_ES
dc.description.sponsorshipNIH grant (R01 AG059752-02)es_ES
dc.language.isoenges_ES
dc.publisherSpringer Naturees_ES
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivs 3.0 Licensees_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es_ES
dc.titleNLRP3 inflammasome activation drives tau pathologyes_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1038/s41586-019-1769-z
dc.type.hasVersionVoRes_ES


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License
Except where otherwise noted, this item's license is described as Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License